deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT06648902

Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue

A Phase 1/2 Study of the Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue.

Sponsor: Kidney Cancer Research Bureau

Conditions Fatigue Related to Cancer Treatment Kidney Cancer Renal Cell Cancer Metastatic
Interventions meldonium
Updated 2 times since 2024 Last updated: Oct 17, 2024 Started: Feb 1, 2022 Primary completion: Sep 1, 2024 Completion: Sep 1, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06648902, this PHASE1/PHASE2 trial focuses on Fatigue Related to Cancer Treatment and Kidney Cancer and remains completed. Sponsored by Kidney Cancer Research Bureau, it has been updated 2 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Nov 2024 – ~Sep 2025 · 10 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

2 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Nov 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

    First recorded

Feb 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Kidney Cancer Research Bureau
Data source: Kidney Cancer Research Bureau

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations